December 2015: SMC decisions
The Scottish Medicines Consortium has accepted the following medicines for use in NHS Scotland for particular indications: efavirenz (Sustiva; Bristol-Myers Squibb); glatiramer acetate (Copaxone; Teva); naloxegol (Moventig; AstraZeneca); ceritinib (Zykadia; Novartis).
Gefitinib (Iressa; AstraZeneca), ivermectin (Soolantra; Galderma), lenalidomide (Revlimid; Celgene) and atomoxetine (Strattera; Eli Lilly) oral solution have been accepted for restricted use. Co-careldopa (Duodopa; AbbVie), denosumab (Xgeva; Amgen) and anakinra (Kineret; Swedish Orphan) are not recommended for use.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200247
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com